Investigational drug · Phase 2
MLD10
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hypomagnesemia in Type 2 Diabetic Patients.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MLD10"
First trial start
2026
Mar 1, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MLD10", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypomagnesemia in Type 2 Diabetic Patients
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "MLD10" as an intervention, largest first.
- MLD10 for the Treatment of Hypomagnesemic Patients With Type 2 Diabetes MellitusPivotal-lookingNot yet recruiting
Pharmalyte Solutions LLCIndustry
NCT03567824 · 200 participants (planned) · Start Mar 1, 2026 · Primary completion Apr 30, 2028
Drug: Magnesium L-lactate dihydrate; Placebo Oral Tablet · For: Hypomagnesemia in Type 2 Diabetic Patients
- MLD10 in the Prevention of Migraine in AdultsPivotal-lookingCompleted
Pharmalyte Solutions LLCIndustry
NCT02322333 · 157 participants · Start Mar 2015 · Primary completion Jun 2017
Drug: MLD10; Placebo · For: Migraine
Sites: Carlsbad, California; San Francisco, California; Oviedo, Florida · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Dose-Response Relationship Between Intracoronary Acetylcholine and Minimal Lumen Diameter in Coronary Endothelial Function Testing of Women and Men With Angina and No Obstructive Coronary Artery Disease.
Pargaonkar VS, Lee JH, Chow EKH, et al. · Circ Cardiovasc Interv 2020
- Kinetics and thermodynamics of ethanol production by Saccharomyces cerevisiae MLD10 using molasses.
Arshad M, Ahmed S, Zia MA, et al. · Appl Biochem Biotechnol 2014
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.